Spotify founder Daniel Ek is bringing his preventive health startup, Neko Health, to the United States, aiming to disrupt the growing full-body scan market with AI-driven diagnostics. The company, which has already raised $260 million in a recent funding round that values it at over $700 million, plans to open its first U.S. clinic in New York City later this year, with rapid expansion across the country.
What Neko Health Offers
Neko Health operates private clinics offering comprehensive full-body scans, blood tests, and cardiovascular assessments using custom-built medical equipment and artificial intelligence. The scans are designed to detect early signs of conditions such as skin cancer, heart disease, and diabetes, with the goal of proactive disease prevention. According to the company, the entire process takes about an hour and provides patients with a detailed health report within minutes.
“Our mission is to catch problems early, prevent disease, and help people live longer. We believe that prevention is the key to a long and healthy life,” said Daniel Ek, co-founder of Neko Health.
Funding and Expansion
Neko Health recently closed a $260 million funding round, bringing its total raised to over $700 million. The round included investments from a star-studded group of celebrities, entrepreneurs, and institutional investors, though the company has not disclosed specific names. The funds will be used to finance the U.S. expansion and further develop its technology. The company already operates clinics in Sweden and the UK, where it has garnered a waiting list of over 100,000 people, as reported by MSN.
Different Perspectives on the Trend
The launch of Neko Health in the U.S. comes amid a growing craze for full-body scans, fueled by a mix of health-conscious consumers and tech entrepreneurs. However, perspectives vary. The New York Times notes that while the scans offer convenience and advanced technology, some medical experts caution that they may lead to overdiagnosis and unnecessary anxiety. The Guardian, which reviewed the service, described the experience as “impressive” but questioned whether the results justify the cost, which is around $299 per scan.
Proponents vs. Skeptics
Proponents, including Ek and other investors, argue that proactive screening can save lives by catching diseases early when they are more treatable. Skeptics, however, point out that many findings may be benign and that the scans could overwhelm the healthcare system with false positives. The company maintains that its AI algorithms are designed to minimize false alarms and that all results are reviewed by medical professionals.
Historical Context and Implications
Neko Health is part of a broader trend of tech entrepreneurs entering the healthcare space, following companies like Theranos (which infamously failed) and more successful ventures such as 23andMe. Ek’s background as the co-founder of Spotify gives him credibility in scaling consumer technology, but healthcare is a heavily regulated industry. The company will need to navigate FDA regulations and state medical licensing laws as it expands.
The implications are significant: if Neko Health succeeds, it could democratize access to advanced diagnostics and shift the focus from reactive to preventive care. However, it also raises questions about data privacy, equity, and the medicalization of healthy individuals.
What’s Next?
Neko Health’s first U.S. clinic is expected to open in Manhattan in late 2025, with plans for additional locations in Los Angeles, Chicago, and other major cities. The company is also exploring partnerships with employers and insurers to make scans more accessible. For now, the waiting list in the UK already exceeds 100,000, indicating strong demand. Whether the U.S. market will embrace the concept with similar enthusiasm remains to be seen.
